Dexcom Reports Third Quarter 2026 Financial Results
Stocks in this Quantisnow insightHealth Care
Historical context for DXCM
Across the 28 sessions after earlier DXCM headlines, the stock closed higher 14 times and lower 14 times, with a median move of 1.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DXCM | SPY |
|---|---|---|---|
| Oct 28, 2026 | Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November | +0.1% | +0.3% |
| Oct 15, 2026 | Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin | +5.1% | +0.3% |
| Oct 7, 2026 | Barclays initiated coverage on Dexcom with a new price targetand 1 other headline that session | +1.1% | -0.2% |
| Oct 6, 2026 | Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading | -4.0% | +0.5% |
| Sep 28, 2026 | Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care | +0.1% | -0.7% |
| Sep 15, 2026 | Dexcom Promotes Jereme Sylvain to Chief Operating Officer | +2.1% | -0.5% |
Quantisnow market dataNASDAQ
DXCM
DexCom Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Listed since
- 2005
Get push alerts for DXCM
Full DXCM profile on Quantisnow Follow DXCM and get a push notification the moment its next story breaks.